Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance

Leukemia. 2013 Dec;27(12):2422-4. doi: 10.1038/leu.2013.126. Epub 2013 Apr 23.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunologic Factors / therapeutic use*
  • Incidence
  • Lenalidomide
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / immunology
  • Prognosis
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use

Substances

  • Immunologic Factors
  • Thalidomide
  • Lenalidomide